News & Events

Filter Year   Keywords   > Submit

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (Centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older

27 / 07 / 2026

> Read More

Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety

25 / 06 / 2026

> Read More

Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

28 / 05 / 2026

> Read More

 
Displaying 3 records